Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RNA based vaccines.

Georgetta Cannon1, Drew Weissman

  • 1Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.

DNA and Cell Biology
|February 8, 2003
PubMed
Summary
This summary is machine-generated.

RNA vaccines offer a promising alternative to DNA vaccines for stimulating CD8(+) T-cell immunity. RNA is readily taken up by dendritic cells, enabling efficient antigen presentation and immune activation for effective vaccine development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies.

Nature·2026
Same author

IgA is necessary and sufficient to prevent norovirus infection in mice.

Science translational medicine·2026
Same author

Decoupling Physisorption from Chemisorption in Clickable Lipid Nanoparticles.

ACS nanoscience Au·2026
Same author

Preventive and therapeutic efficacy of mRNA/LNP vaccines encoding HPV16 E6 and E7 in an early-intervention HPV tumor mouse models.

Human vaccines & immunotherapeutics·2026
Same author

Bioinspired oxidized mRNA lipid nanoparticles for ex vivo engineering of chimeric antigen receptor macrophages targeting solid tumors.

Bioengineering & translational medicine·2026
Same author

Antigen-specific messenger RNA lipid nanoparticle therapy with mTOR inhibition promotes regulatory T cells and limits allergy.

The Journal of allergy and clinical immunology·2026
Same journal

Fibroblast Growth Factor 18 Regulates Mitochondrial Function to Alleviate Myocardial Ischemia-Reperfusion Injury in Rats.

DNA and cell biology·2026
Same journal

Silencing Long Noncoding RNA <i>CRNDE</i> Alleviates Hypoxia-Induced Myocardial Cell Injury by Inhibiting the NLRP3/ASC Pathway.

DNA and cell biology·2026
Same journal

Integrated Multi-Omics Profiling Reveals Coordinated Transcriptional, Translational, and Metabolic Remodeling in IPF Fibroblasts.

DNA and cell biology·2026
Same journal

The Innate Immune Protein IFITM3 as a γ-Secretase Modulatory Protein: From Inflammation to Alzheimer's Disease.

DNA and cell biology·2026
Same journal

Glycosyltransferases as Oncogenic Drivers: Lessons from Cancer Genome Mining.

DNA and cell biology·2026
Same journal

Essential Role for XRCC1 and PARP1 in the Repair of Genotoxic Damage During Spermatogenesis.

DNA and cell biology·2026
See all related articles

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • CD8(+) T-cell mediated Th1 immune responses are crucial for immunity against intracellular and transformed pathogens.
  • Conventional vaccines often present antigens extracellularly, primarily activating CD4(+) T cells via MHC class II.
  • Nucleic acid-based vaccines aim to induce CD8(+) T-cell responses by enabling intracellular antigen production.

Purpose of the Study:

  • To explore the potential of RNA as a vaccine candidate for inducing CD8(+) T-cell mediated immunity.
  • To discuss the immune responses generated by RNA delivery to antigen-presenting cells (APCs).
  • To examine the interactions between APCs and RNA that drive dendritic cell (DC) activation.

Main Methods:

  • Review of existing literature on nucleic acid vaccine delivery and immune responses.

Related Experiment Videos

  • Discussion of dendritic cell (DC) transfection and antigen presentation pathways.
  • Analysis of in vitro and in vivo studies investigating RNA-based immunizations.

    • Main Results:

    • DNA delivery to DCs for vaccination is inefficient, requiring high concentrations and repeated doses.
    • RNA is readily taken up and expressed by DCs, facilitating MHC class I presentation.
    • Preliminary studies suggest RNA can induce protective immunity.

    Conclusions:

    • RNA vaccines are a viable alternative to DNA vaccines for eliciting CD8(+) T-cell responses.
    • The efficient uptake and expression of RNA by DCs are key to its vaccine potential.
    • Further in vivo and in vitro studies are warranted to fully develop RNA-based protective immunity.